Increased awareness of the risk of cardiovascular disease (CVD) in postmenopausal women will aid clinicians in choosing the most appropriate hormone therapy (HT) for their patients. An antialdosterone-containing hormonal therapy offers postmenopausal women advantages beyond simply the relief of menopausal symptoms; drospirenone/estradiol therapy has a theoretical advantage for the modulation of postmenopausal cardiovascular target organ complications. Additionally, drospirenone/ estradiol therapy represents an attractive alternative to other forms of HT.